TY - JOUR
T1 - HPV vaccination crisis in Japan
AU - Hanley, Sharon J. B.
AU - Yoshioka, Eiji
AU - Ito, Yoshiya
AU - Kishi, Reiko
N1 - We thank Keisuke Tamori and Julia Brotherton for their advice.
SJBH is part of the executive board of the People's Campaign Against Female Cancers (PCAF) and a committee member of the Japanese Expert Board for the Eradication of Cervical Cancer. SJBH reports lecture fees from Japan Vaccine and the Japanese Expert Board for the Eradication of Cervical Cancer. PCAF and the Japanese Expert Board for the Eradication of Cervical Cancer have received funding from Japan Vaccine and Merck Sharp and Dohme. EY, YI, and RK declare no competing interests.
PY - 2015/6/27
Y1 - 2015/6/27
N2 - Free vaccination against the human papillomavirus (HPV) began in December, 2010, for Japanese girls aged 12–16 years and since April, 2013, the vaccine was included in the national immunisation programme. However, in June, 2013, the Japanese Ministry of Health, Labour, and Welfare suspended proactive recommendations for the HPV vaccine after unconfirmed reports of adverse events following vaccination appeared in the media.1 In January, 2014, the Vaccine Adverse Reactions Review Committee investigating these adverse events concluded that there was no evidence to suggest a causal association between the HPV vaccine and the reported adverse events after vaccination, but they still did not reinstate proactive recommendations for its use.2 We report the resulting effects of such a decision by presenting data from Sapporo, a city of 2 million people in northern Japan.
AB - Free vaccination against the human papillomavirus (HPV) began in December, 2010, for Japanese girls aged 12–16 years and since April, 2013, the vaccine was included in the national immunisation programme. However, in June, 2013, the Japanese Ministry of Health, Labour, and Welfare suspended proactive recommendations for the HPV vaccine after unconfirmed reports of adverse events following vaccination appeared in the media.1 In January, 2014, the Vaccine Adverse Reactions Review Committee investigating these adverse events concluded that there was no evidence to suggest a causal association between the HPV vaccine and the reported adverse events after vaccination, but they still did not reinstate proactive recommendations for its use.2 We report the resulting effects of such a decision by presenting data from Sapporo, a city of 2 million people in northern Japan.
KW - Female
KW - Humans
KW - Adolescent
KW - Child
KW - Japan
KW - Mass Screening/organization & administration/statistics & numerical data
KW - Mothers/statistics & numerical data
KW - Papillomavirus Vaccines/administration & dosage/adverse effects
KW - Patient Acceptance of Health Care/statistics & numerical data
KW - Uterine Cervical Neoplasms/prevention & control
KW - Vaccination/statistics & numerical data
U2 - 10.1016/S0140-6736(15)61152-7
DO - 10.1016/S0140-6736(15)61152-7
M3 - Letter
VL - 385
SP - 2571
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9987
ER -
